Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523640 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00523640 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 30 participants.
The verdict
NCT00523640, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) the combination of the chemotherapy drugs gemcitabine, capecitabine, and bevacizumab has on a patient and kidney cancer.
Interventions
- DRUG combination of gemcitabine, capecitabine, and bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523640
The ClinicalTrials.gov registry entry for NCT00523640 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which combination of gemcitabine, capecitabine, and bevacizumab is the first listed.
NCT00523640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00523640 about?
NCT00523640 is a clinical study titled "A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma". The purpose of this study is to find out what effects (good and bad) the combination of the chemotherapy drugs gemcitabine, capecitabine, and bevacizumab has on a patient and kidney cancer.
What is the current status of trial NCT00523640?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00523640?
The interventions under investigation include: combination of gemcitabine, capecitabine, and bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00523640?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.